Merck Gets CHMP Backing of Winrevair in Pulmonary Arterial Hypertension
By Colin Kellaher
Merck & Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Winrevair for pulmonary arterial hypertension, or PAH.
The Rahway, N.J., drugmaker said the recommendation covers Winrevair in combination with other PAH therapies in adults with the potentially fatal lung disease.
The European Commission, which generally follows CHMP's advice, will now review the recommendation, with a decision expected in the third quarter.
The U.S. Food and Drug Administration in March approved Winrevair, which was the key drug in Merck's $11.5 billion acquisition of Acceleron Pharma in 2021 and is the subject of a licensing agreement with Bristol Myers Squibb.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 28, 2024 07:33 ET (11:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations